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Abstract
Tumor metastasis is a complex phenomenon that is the culmination of effects of numerous cellular 
factors. We have shown that the EBV oncoprotein, latent membrane protein 1 (LMP1), is capable 
of inducing a wide range of such factors in cell culture, expression of which is also elevated in the 
LMP1-expressing tumor, nasopharyngeal carcinoma (NPC), a highly invasive neoplasm. Recently, 
the membrane-crosslinker protein ezrin has been implicated in tumor cell metastasis and 
malignant progression. In this study, we evaluated the possible role of LMP1 and ezrin in the 
pathophysiology of NPC. We show that C-terminal phosphorylation of ezrin is increased by 
expression of LMP1 in nasopharyngeal (NP) cells through a Protein Kinase C (PKC) pathway. 
LMP1 enhances organization of a ternary complex of CD44, ezrin and F-actin which is a 
prerequisite for ezrin phosphorylation. In NPC tissues, expression of phosphoezrin and LMP1 is 
directly correlated. Silencing of endogenously expressed ezrin suppresses LMP1-induced cell 
motility and invasiveness. Moreover inhibition of ezrin phosphorylation by PKC inhibitor 
suppresses migration and invasion of NP cells. These data demonstrate that phosphorylation of 
ezrin and its recruitment to the cell membrane linked to F-actin and CD44 is a process required for 
LMP1-stimulated cell motility and invasion of NP cells.
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From a worldwide perspective NPC is the most important tumor associated with EBV 
infection. NPC is latently infected with the virus, and monoclonal EBV episomes are present 
and expressed in the tumor cells in both endemic and sporadic forms of NPC regardless of 
geographic origin. The EBV protein LMP1 is detected in most NPC, which classically 
displays a type II latent gene expression profile that consists of EBNA1, LMP1, LMP2a, 
LMP2b and EBERs. Among them LMP1 the principal oncoprotein is considered to be a key 
factor in NPC development (Tsao SW et al., 2002; Lo et al., 2004).
Among head-and-neck cancers NPC is distinguished by its highly metastatic character and 
poor prognosis (Lo et al., 2004). LMP1 is known to elicit its oncogenic properties by 
constitutively activating multiple signaling pathways, such as NF-κB, c-Jun, AP-1, JAK3/
STAT, p38MAPK and, recently identified, the PKC pathway (Yan et al., 2007). We have 
shown that LMP1 induces the expression of a series of cell-invasiveness and angiogenetic 
factors and their effects in nasopharyngeal (NP) cells, including matrix metalloproteinase 9 
(MMP9) (Yoshizaki et al., 1998), MMP1, MMP3 (Kondo et al., 2005), c-Met and ets-1 
(Horikawa et al., 2001), fibroblast growth factor 2 (FGF-2) (Wakisaka et al., 2002), vascular 
endothelial factor (VEGF) (Murono et al., 2001), hypoxia-inducible factor 1 (HIF 1α) 
(Wakisaka et al., 2004), MUC1 (Kondo et al., 2007), Siah 1 (Kondo et al., 2006), and Twist 
(Horikawa et al., 2007). Several of these factors are expressed in NPC tissues in association 
with LMP1 and are thought to be involved in invasion and metastasis of NPC (Yoshizaki et 
al., 2005).
The ability of primary tumor cells to migrate is an early contributor to tumor cell metastasis. 
Cell migration is a highly regulated process that shapes the organization of every tissue in 
the body (Hopkins et al., 2007). Recently, it has been reported that ezrin modulates 
remodeling of actin cytoskeleton and is implicated in tumor cell migration and progression 
of certain tumors (Khanna et al., 2004; Bruce et al., 2007; Fais et al., 2004).
Ezrin is a member of the ezrin/moesin/radixin (ERM) family that acts as linker between the 
plasma membrane and the actin cytoskeleton and generates propulsive forces driving cell 
migration (Hopkins et al., 2007). ERM proteins are highly homologous to one another and 
there is no clear functional difference among them (Martin et al., 2003). The ERM family 
exhibits a tissue-specific expression pattern; Ezrin is the most ubiquitous ERM protein in 
epithelial cells and thought to play an important role in progression of several cancers 
(Khanna et al., 2004; Auvinen et al., 2007). Moesin is enriched in endothelial cells and 
leukocytes, and radixin is abundant in liver (Doi et al., 1998). In the cytoplasm, ezrin exists 
in an autoinhibited conformation through an intramolecular interaction between its N-
terminal and C-terminal domains or through formation of oligomers that include ezrin and 
other ERM proteins. This interaction masks membrane and F-actin binding sites. Cellular 
signals trigger the activation of ezrin, resulting in the unmasking of the functional binding 
sites (Auvinen et al., 2007, Louvet-Vallée, 2000). Several residues of ezrin have recently 
been found to be phosphorylated and in that state functionally active (Louvet-Vallée, 2000). 
Specifically, the phosphorylation of ezrin on its C-terminal threonine 567 unmasks its 
binding sites for actin and cell membrane in its conformationally activated form (Fievet et 
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al., 2004). In this state ezrin moves to the cell membrane and tethers actin to it, which also 
affects the architecture and dynamics of the actin cytoskeleton. Basic to these functional 
effects is the phosphorylation of ezrin which occurs upon stimulation of cells with 
hepatocyte growth factor (HGF) or epidermal growth factor (EGF) or androgen, resulting in 
modification of cell morphology (Crepaldi et al., 1997; Chuan et al., 2006).
Central functions of ezrin are regulation of cell shape, motility, adhesion and signal 
transduction, all of which are important for tumor development and progression (Fais et al., 
2004). Here we analyze phosphorylation and activation of ezrin induced by LMP1 and show 
that phosphoezrin localizes predominantly in the cell membrane linked to CD44 and that the 
depletion of ezrin by small interfering RNA significantly attenuates LMP1-stimulated cell 
motility and invasion. Also, in NPC tissues expression of phosphoezrin and LMP1 is 
directly correlated.
Results
LMP1 phosphorylates ezrin at Thr 567 but does not induce its expression
To investigate whether LpMP1 affects the induction or the phosphorylation of ezrin, we 
used a nonmalignant EBV-negative nasopharyngeal cell line, Ad-AH. No effect on level of 
ezrin protein waps produced by expression of LMP1. However phosphorylation of ezrin 
detected with phosphoezrin antibody, which recognizes only protein phosphorylated on 
Thr567 in the C-terminal region, significantly increased in both transiently and stably 
transfected cells (Fig. 1A). Although phosphorylated moesin and radixin might be detected, 
ezrin is the most ubiquitous ERM protein in epithelial cells. We next investigated 
endogeneous levels of phosphoezrin in a set of type II latently EBV-infected cell lines, KH1 
and KH2, which were derived by somatic-cell fusion of a latently EBV-infected type III 
lymphoblastoid KR4 cell line with Hela cells (Contreras-Brodin et al., 1991). Hela cells 
stimulated with EGF were used as a positive control for phosphorylation of ezrin 
(Baumgartner et al., 2006). In both type II cell lines, endogenous phosphoezrin levels were 
higher than in the parental Hela cells, which are EBV-negative (Fig. 1B).
To examine the viral mechanism of phosphorylation, we used mutants of expression 
plasmids of the principal LMP1 intracellular signaling domains, CTAR1 and CTAR2. LMP1 
1–187, which has both CTAR1 and CTAR2 deleted, had no effect on the phosphorylation of 
ezrin. Both LMP1 1–231, which has CTAR1 only, and LMP1 del 187–351, which has 
CTAR2 only, induced phosphoezrin, but phosphorylation was weaker than when induced by 
LMP1-WT (Fig. 1C). These findings indicate that LMP1 can produce an increase in ezrin 
Thr567 phosphorylation in NP cells, and that LMP1 CTAR1 and CTAR2 both participate.
LMP1 modulates translocation of ezrin from the cytosol to the plasma membrane
C-terminal phosphorylated ezrin is known to be activated and recruited to the plasma 
membrane (Gautreau et al., 2002). We investigated the localization of endogenous ezrin 
phosphorylated by LMP1 by using another nonmalignant EBV-negative nasopharyngeal cell 
line, NP69. In LMP1-expressing NP69 cells, the level of phosphoezrin was increased 
compared with parental control NP69 cells (Fig. 2A); results were similar to those obtained 
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with Ad-AH cells (Fig 1A). Fig. 2B shows that in control NP cells, ezrin is present in the 
cytosol and also in cell-cell contacts, which means that most of the ezrin exists in an inactive 
form. However in LMP1-expressing cells, ezrin was detected in plasma membrane. 
Subcellular fractionation verified this shift in ezrin distribution caused by LMP1: ezrin and 
phosphoezrin were mostly detected in the cytosol fraction, but only in the plasma membrane 
fraction in LMP1-expressing cells (Fig. 2C). Moreover, immunofluorescence analysis 
revealed phosphoezrin in plasma membrane (Fig. 2D). Thus LMP1 mediates translocation of 
ezrin from the cytoplasm to the cell membrane, which indicates that phosphorylated ezrin is 
activated and is positioned to function as a cross-linker protein between adhesion molecules 
and actin cytoskeleton.
LMP1 modulates phosphorylation of ERM protein, which links to CD44
Phosphorylation of ezrin on Thr567 is reported to activate and disrupt intramolecular 
association and changes in ezrin localization; formation of actin-rich structures near the cell 
membrane are also produced by phosphorylation of ezrin on Thr567 (Fievet et al., 2004; 
Gautreau et al., 2002). To look for potential binding candidates for ezrin, we evaluated 
which membrane-anchored cell-adhesion molecule binds phosphorylated ezrin. LMP1 is 
reported to be associated with ICAM-1 and CD44 (Walter et al., 1995; Park et al., 2002). 
Fig. 3A shows that in LMP1-expressing cells ezrin could be coprecipitated by CD44 
antibody. In addition CD44 could be coprecipitated by ezrin antibody in LMP1-exressing 
cells (Fig. 3B) Double-staining with CD44 and ezrin antibodies showed that both proteins 
were co-localized at the plasma membrane in LMP1-expressing cells (Fig. 3C). Interaction 
of ezrin with ICAM-1 was not detected by IP (data not shown). These data suggest that ezrin 
as modulated by LMP1 is recruited to the cell membrane and forms crosslinks between 
CD44 and actin cytoskeleton.
Expression of phosphoezrin correlates directly with LMP1-positivity in NPC tissue
Based on the results in the cell-culture models, we next tested whether phosphoezrin could 
be detected in LMP-positive NPC tissues (see details in Material and Methods). 
Immunohistochemical staining revealed phosphoezrin mainly in plasma membrane and 
cytoplasm of the tumor cells (Fig. 4A). LMP1 protein was also located in the membrane and 
cytoplasm (Fig. 4B). Expression scores for phosphoezrin and LMP1 were closely correlated 
(r=0.676; p<0.001) (Fig. 4C). These results support the conclusion that LMP1 induces the 
C-terminal phosphorylation of ezrin not only in cell culture but in tumor tissue in vivo.
Ezrin plays a pivotal role in LMP1-stimulated cell morphology, motility and invasiveness
The regulation of cell shape, motility and invasiveness by ezrin in its phosphorylated state is 
well documented (Khanna et al., 2004; Chuan et al., 2006). We therefore studied the 
contribution of LMP1-indeced phosphoezrin to such properties by the use of siRNA 
targeting ezrin. LMP1-expressing NP cells characteristically have a spindle-like fibroblastic 
appearance whereas control cells have a cobble-stone-like morphology (Fig. 5A). The 
fibroblastic appearance disappears in LMP1-expressing cells transfected with ezrin siRNA. 
Expression of ezrin protein was barely detectable in these cells (Fig. 5B). Thus, ezrin is 
involved in control of NP cell shape.
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Next we assessed the role of ezrin in LMP1-stimulated cell invasiveness. LMP1 
significantly enhanced both cell motility in wound-scratch assays (see Material and 
Methods) and invasiveness in Matrigel invasion assays. All these LMP1-induced phenotypes 
were significantly suppressed by ezrin siRNA (Fig. 6C, D). These data suggest that ezrin is a 
downstream target of LMP1-induced signaling and is essential for a critical step in the 
metastatic phenotype induced by LMP1.
LMP1 enhances ezrin phosphorylation through PKC not Rho/ROCK pathways
Activation of ezrin involves phosphorylation of specific carboxyl-terminal threonine 
residues through several serine/threonine kinases known to phosphorylate ezrin on a C-
terminal threonine (Louvet-Vallée, 2000; Fievet et al., 2004). Two major pathways have 
been implicated. One is the small GTP-binding protein Rho and the ROCK pathway (Tran et 
al., 2000). The other is the Protein Kinase C (PKC) pathway (Ng et al., 2001; Larsson et al., 
2006). To examine which might account for the phosphorylation of ezrin in LMP1-
expressing cells, we used two inhibitors. Y27632, an inhibitor of Rho-associated protein 
kinase (ROCK), had no effect on LMP1-stimulated phosphorylation of ezrin, suggesting that 
ezrin is not a substrate for Rho kinase in NP cells (Fig. 6A). In contrast, pretreatment with 
Gö6976, a PKC inhibitor, dramatically inhibited LMP1 stimulation of Thr567 
phosphorylation (Fig. 6B). LMP1 has been reported to enhance PKC activity, which engages 
multiple signaling pathways of LMP1 (Yan et al., 2007; Zheng et al., 2007), and these data 
point to PKC as an activator of ezrin in LMP1-expressing cells.
Since LMP1 expression in NP cells is known to induce on invasive phenotype (Tsao et al., 
2002, 4), we next examined with the use of the two inhibitors the contribution of 
phosphorylation state of ezrin to cell motility and invasiveness, in wound-scratch and 
Matrigel invasion assays. In LMP1-expressing NP69 cells, which have approximately five-
fold increased cell motility and invasiveness compared with control cells (Fig. 6C, D) 
Gö6976 completely suppressed LMP1-enhanced cell motility and invasiveness, whereas 
Y27632 had no effect. Thus LMP1 induces PKC-mediated phosphorylation of ezrin, which 
leads to increases in effects on cell motility and invasiveness of NP cells. These data stress 
that ezrin phosphorylation is required for LMP1-stimulated cell motility and invasiveness.
Discussion
The oncogenic properties of LMP1, the principal EBV oncoprotein, are numerous and 
continue to be elaborated (Yoshizaki et al., 2005). The association of the virus and NPC 
from its inception is virtually universal, and it is likely but not strictly proven that EBV 
contributes etiologically to this distinctive malignancy. However in addition there is strong 
experimental and pathobiological evidence that LMP1 also affects late stages of oncogenesis 
through its ability to induce and activate a plethora of cellular factors that promote cell 
invasion and metastasis as well as angiogenesis. Initiation of this highly complex process is 
marked by increases in tumor cell motility. We have shown previously that LMP1 can 
induce matrix metalloproteinase 9 (MMP9) (Yoshizaki et al., 1998), MMP1, MMP3 (Kondo 
et al., 2005), c-Met and ets-1 (Horikawa et al., 2001), and Twist (Horikawa et al., 2007), all 
of which produce increases in cell motility and invasiveness.
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In this paper, we return to cell motility, but from a quite distinct perspective, namely, 
through the ERM family proteins typified by ezrin. We show here for the first time that in 
addition to HGF, EGF and androgen, the viral factor, LMP1, can enhance formation of a 
complex of CD44, ezrin and F-actin which permits phosphorylation of ezrin through PKC 
and results in increased cell motility and invasiveness which is neutralized by silencing 
expression of ezrin (Fig. 7). Moreover in NPC tissues, there is direct correlation between 
expression of phosphoezrin and LMP1. LMP1 activates multiple signaling cascades, NF-kB, 
MAPK, JNK, p38 and JAK/STAT, involved in cell immortalization, cell proliferation, and 
apoptosis (Zheng et al., 2007). Ezrin is essential for cortical cytoskeleton organization, cell 
shape, motility, adhesion and intracellular signaling and has been associated with malignant 
progression and metastasis in human neoplasias such as melanoma, lung and endometrial 
carcinoma, rhabdomyosarcoma, and osteosarcoma (Khanna et al., 2004; Bruce et al., 2007; 
Fais et al., 2004). Ezrin is highly expressed in most normal epithelial tissue as well as many 
cancers, but normal mesenchymal tissues have relatively low levels of ezrin (Bruce et al., 
2007), suggesting that there are tissue-specific functions for ezrin. Ezrin overexpression in 
prostate cancer cells is alone not sufficient to promote cell invasiveness (Chuan et al., 2006). 
According to these studies, evaluating ezrin in the active state is more important in 
malignant behavior than the expression of total ezrin because of the ubiquitousness of ezrin 
in cancer as well as normal epithelial tissues.
Ezrin can exist both in inactive and in active forms, and phosphorylation of ezrin regulates 
its activities (Louvet-Vallée, 2000). Phosphorylation of the conserved C-terminal threonine 
residue within the actin-binding site of ezrin is the major mechanism for regulating 
conformational changes and functional activities of ezrin (Fievet et al., 2004). Several 
protein kinases are known to phosphorylate ezrin on the C-terminal threonine, including 
Rho/ROCK and PKC (Tran et al., 2000; Ng et al., 2001; Larsson et al., 2006). According to 
our findings, LMP1-induced PKC is required for phosphorylation of ezrin and its 
translocation from the cytosol to the cell membrane. PKC comprises a family of 
phospholipid-dependent serine/threonine kinases that regulates a large number of cellular 
processes, such as cell spreading and migration. PKC isoforms constitute a family of 10–15 
members, and the different isoforms have unique effects in cellular regulation (Larsson et 
al., 2006). Among these isoforms, classical PKCα is known to bind and phosphorylate ezrin 
in fibrosarcoma cells (Ng et al., 2001). Overexpression of PKCα in MCF-10A human breast 
cells enhances cell motility (Sun et al., 1999). A recent study showed that LMP1 could 
activate the PKCα/PKCβ pathway (Yan et al., 2007; Zheng et al., 2007). Our data show that 
a selective PKCα, but not a Rho/ROCK, inhibitor Gö6976, which interacts with the ATP-
binding site, decreased ezrin phosphorylation modulated by LMP1. Moreover inhibition of 
PKC markedly decreased LMP1-stimulated cell migration and invasion, consistent with 
previous reports (Chuan et al., 2006; Ng et al., 2001). However in a previous study, 
epithelial cells exposed to ROCK inhibitor exhibited increased cell motility and invasiveness 
(Hopkins et al., 2007), which was explained by an illusory enhancement of cell spreading, 
produced by stimulation of cell protrusiveness at the migrating front. Our data indicate that 
ezrin phosphorylation is required for LMP1-induced cell motility and invasiveness.
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Once ezrin is phosphorylated and translocates to the plasma membrane, it interacts with a 
number of cell-surface adhesion molecules, including ICAM-1, -2, -3, CD43 and CD44 
through its N-terminus and links to actin through its C-terminus (Martin et al., 2003). Our 
observations reveal that ezrin in its active state as modulated by LMP1 links to CD44, the 
major cell-surface hyaluronan receptor expressed in diverse cell types. Cellular functions 
that affect the ability of tumor cells to migrate within tissues, transmigrate through vessels 
and adhere to adjacent and distant organs are contributors to metastasis early in the process. 
CD44 itself can affect cell migration and metastasis (Martin et al., 2003). Further, PKC 
regulates the interaction between CD44 and ezrin as this complex regulates cell migration 
(Ng et al., 2001; Orian-Rousseau et al., 2002). PKC activation leads to dephosphorylation of 
S 325 and at the same time phosphorylation of S 291 in CD44 (Legg et al., 2002). Thus 
PKC activated by LMP1 may regulate cellular motility by controlling phosphorylation of 
both ezrin and CD44. Moreover, ezrin/CD44 complex is known to organize kinase signaling 
cascades, such as PI3k/AKT (Martin et al., 2003). We have previously shown that c-met 
induced by LMP1 is associated with cell motility in NPC (Horikawa et al., 2001). Since c-
met can form a multimeric complex with HGF which induces phosphorylation of ezrin, we 
hypothesize that there may be signaling crosstalk between ezrin and c-met induced by 
LMP1.
We provide here novel data showing that downregulation of ezrin in LMP1-stimulated NP 
cells results in decreased cell motility and invasiveness. In other studies, Ezrin has been 
implicated in cytoskeleton-mediated cell motility via regulation of cell shape. Recent study 
shows that silencing of ezrin induces increased E-cadherin expression which is central to the 
process of epithelial cell-cell adhesion (Hiscox et al., 1999). Use of ezrin siRNA or 
dominant-negative ezrin has revealed that this protein is a key factor in the development of 
metastasis in some cancers (Khanna et al., 2004; Chuan et al., 2006). Our findings that 
silencing of expression of ezrin inhibits LMP1-induced cell motility and invasion and that 
detection of phosphoezrin correlates directly with LMP1-positivity in NPC, suggests 
perhaps a unique role for ezrin in NPC oncogenesis.
We provide here the first evidence that control of phosphorylation and relocation of ezrin by 
LMP1 regulates cell migration and invasiveness. Understanding of ezrin function and its 
binding partners in NPC could potentially provide much needed new targets for therapeutic 
agents that intercept metastasis of this highly invasive malignancy.
Material and Methods
Cell lines and drug treatment
Ad-AH cells, an EBV-negative human nasopharyngeal cell line, were kindly provided by 
Dr. Erik K. Flemington (Tulane University, New Orleans, LA) (Takimoto et al., 1998) and 
maintained in DMEM. NP69 and NP69LMP1, human immortalized nasopharyngeal 
epithelial cells, generous gifts of Dr. Sai Wai Tsao (University of Hong Kong, Hong Kong, 
China), were maintained in Keratinocyte-SFM (Tsao et al., 2002). KH-1 and KH-2 are 
EBV-positive type II cell lines derived by fusion of KR4 (an EBV-positive type III 
lymphoblastoid cell line) and Hela cells (human cervical carcinoma), kind gifts of Dr. Maria 
Masucci, (Karolinska Institute, Stockholm, Sweden) (Crepaldi et al., 1997).
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Epidermal Growth Factor (EGF) was purchased from Sigma (St. Louis, Mo). Cells 
incubated with EGF (25 nM) for one hour. Inhibitors of Rho kinase Y-27632, PKCα 
Gö6976 were from Calbiochem, San Diego, CA. To evaluate the role of Rho kinase or PKC, 
cells were pretreated with either vehicle Y-27632 (20 μM) or Gö6976 (1 μM) for 30 min.
Plasmids and antibodies
pcDNA3-based LMP1 plasmid (Raab-Traub et al., 1987) and flag-tagged LMP1 mutants 
(LMP1 1–231, LMP1 del 187–351, LMP1 1–187) and LMP1 WT have been described 
(Miller, W. et al., 1997).
Rabbit monoclonal ezrin antibody and rabbit polyclonal phosphoezrin antibody (Thr-567) 
were purchased from Cell Signaling (Beverly, MA). Mouse CD44 antibody was from Sigma 
(St. Louis, Mo). Mouse LMP1 antibody was from DAKO (Glostrup, Denmark). Horseradish 
peroxidase-conjugated mouse or rabbit secondary antibody was from Amersham (Little 
Chalfont, United Kingdom)
Ezrin shRNA
For an ezrin shRNA-expressing cell line, retroviruses that encode ezrin shRNA were 
constructed by ligating ezrin oligonucleotide, (GGCUUUCCUUGGAGUGAAA) into a 
pSuper-retro vector (Oligoengine) (Zhang et al., 2006). Lipofectamine 2000 (Invitrogen) 
was used for transfection of NP69 cells, transfected cells were selected with puromycin 
(Stewart et al., 2003). A negative control cell line was generated by infecting cells with 
pSuper-puro construct targeting GFP (GCTACGTCCAGGAGGGCAC).
Western blot analysis
Extracts of cellular proteins were prepared as described previously (Wakisaka et al., 2002). 
Cell lysates were electrophoresed and transferred to nitrocellulose membrane. Protein 
concentration was determined by Bradfold assay (Bio-Rad). Membranes were blocked with 
nonfat dry milk in TBS and probed with primary antibody overnight, followed by 
corresponding secondary antibody. Antibody-bound proteins were visualized by the 
SuperSignal chemiluminescence system (Pierce, Rockford, IL ).
Immunoprecipitation
Whole-cell lysates were precleared with A/G PLUS-Agarose beads and incubated with 
CD44 (Santa Cruz Biotechnology) or ezrin antibody and then incubated with beads 
overnight. After intensive washing and centrifugation, immune complexes were separated 
by SDS/PAGE and probed with primary antibody by western blotting.
Immunofluorescence staining
Cells cultured on glass coverslips were fixed with 4% paraformaldehyde, washed with PBS, 
permeabilized with 0.5% Triton-X-100/PBS and blocked with 0.5% normal donkey serum. 
Cells were then incubated with primary antibodies to ezrin, phosphoezrin, and CD44 
overnight and were the same as used for Western blotting.
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Cellular fractions were obtained with a Qproteome Cell Compartment kit (Qiagen). 
Cytosolic and membrane proteins were obtained with specific extraction buffer according to 
the manufacturer’s instructions
Immunohistochemical analysis of NPC tissues
Primary NPC paraffin-embedded specimens from Kanazawa University Hospital (Ishikawa, 
Japan) Fukui Saiseikai Hospital (Fukui, Japan), Toyama City Hospital (Toyama, Japan) and 
Kurobe City Hospital (Toyama, Japan) were used for detection of LMP1 and phosphoezrin. 
Specimens were from 24 men and 5 women, ages 24 to 90 years (mean 56.3 years), and 
classified histologically as follows: 2 squamous cell carcinomas (WHO type I), 17 
nonkeratinizing carcinomas (type II), and 10 undifferentiated carcinomas (type III): one 
stage IIA, four stage IIB, nine stage III, 12 stage IVA, and three stage IVB (5th TNM 
classification system of the International Union Against Cancer (1997)). Twenty-Two of 29 
specimens were EBV-positive, 4 were equivocal, and 3 were negative on the basis of EBER 
staining. For complete details see supplementary table 1. Immunohistochemistry was done 
described before (Horikawa et al., 2001). Primary antibodies for LMP1 and phosphoezrin 
were the same as for Western blotting. Stained samples of phosphoezrin and LMP1 were 
evaluated as follows: using light microscopy, number of stained cells from 200 cells was 
carefully counted in the two areas in a 200x field without any clinicopathological knowledge 
of the patients. The percentage of positive cells obtained as an average of two counts was 
used as the expression score for both proteins.
Invasiveness and cell wound-migration assays
Matrigel was purchased from BD Bioscience and stored at −20°C. After dilution in serum-
free medium, 50 μl of Matrigel suspension were inoculated onto the upper chamber. 
Matrigel invasiveness assays were carried out according to the manufacturer’s instructions. 
After 72 h, cells adherent to the lower surface of filters were fixed, stained, and scores 
calculated from counts of cells invading through the Matrigel-coated membrane. Cell 
wound-migration assay was done as described previously (Horikawa et al., 2001). Briefly, 
confluent cell monolayers were scratched with a micropipette tip, and spontaneous cell 
migration was monitored for 24 h. The distance to wound closure was measured in five 
independent sites per group. Migration was assessed by measuring distances between wound 
edges.
Statistical analysis
Pearson’s correlation coefficient was used to analyze correlations between the expression of 
LMP1 and phosphoezrin in NPC specimens. The differences in wound migration and 
invasiveness indices between NP69 cell clones were analyzed by the paired t test. Error bars 
indicate SD of the mean, and significance was defined at the level of p<0.05. All 
experiments were repeated at least three times.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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LMP1 increases phosphorylation of ezrin in nasopharyngeal epithelial cells. A, Immunoblot 
analyses of phosphoezrin and LMP1 in Ad-AH cells: transient (left) or stable (right) LMP1 
transfectants. B, In type II latently EBV-infected lines, KH1 and KH2, phosphoezrin level 
was higher than in EBV-negative parental Hela cells. Hela cell stimulated with EGF (25 
nM) served as positive control for phosphorylation. C, Ezrin is phosphorylated by both 
LMP1 CTAR1 and CTAR2. LMP1 1–231 retains CTAR1 only, LMP1 del 187–351 has 
CTAR2 only, and LMP1 1–187 has both CTAR1 and CTAR2 deleted.
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Localization of ezrin in NP69 cells. A, Immunoblot analysis of phosphoezrin in NP69 cells 
stably expressing LMP1. B, Immunofluorescence analyses. In control NP69 cells, most ezrin 
staining was localized at cell-cell contacts and cytoplasm, while in NP69-LMP1 expressing 
cells, ezrin was detected in cell membrane. B, Cells stained by p-ezrin antibody. C, Ezrin 
and phosphoezrin distribution in subcellular fractions. Equal amounts of proteins from 
membrane-enriched and cytosol fractions were probed with ezrin and phosphoezrin 
antibody. Ezrin and phosphoezrin were detected in membrane fraction only in LMP1-
expressing cells. D, Immunofluorescence analyses of NP69 cells stained by phosphoezrin 
antibody. In NP69-LMP1 expressing cells, phosphoezrin was detected in plasma membrane. 
Bar=10 μm
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Ezrin closslinks with CD44 in LMP1-expressing cells. A, Ezrin is immunoprecipitated from 
NP69 cells by CD44 antibody. LMP1 increases coprecipitation of CD44 and ezrin. B, CD44 
is immunoprecipitated from NP69 cells by ezrin antibody. C, In LMP1-expressing NP69 
cells, ezrin and CD44 colocalize in the cytosol and cell membrane. NP69 cells were 
immunostained for ezrin (green), CD44 (red) and nuclei (blue). Right panel is higher power 
view of lower right area in NP69 LMP1-expressing cells. Arrows indicate colocalization of 
ezrin with CD44. Bar=10 μm
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Expression of phosphoezrin and LMP1 proteins in NPC tissues. A, Detection of LMP1 in 
NPC by immunohistochemistry. LMP1 is detected mainly in cytoplasm and plasma 
membrane. B, Detection of phosphoezrin in NPC. phosphoezrin is visible in cytoplasm and 
plasma membrane. C, Expression scores for LMP1 and phosphoezrin in the 29 NPC 
specimens. Average percentages of tumor cells staining for LMP1 and p-ezrin are plotted. 
Expression scores (see Material and methods) for LMP1 and p-ezrin correlated significantly. 
Pearson correlation coefficient, r=0.676; p<0.001.
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Ezrin contributes to LMP1-induced changes in cell phenotype. A, LMP1 induces fibroblast-
like morphology in NP69 cells that disappears with ezrin siRNA. Bar, 50 μm. B, Reduction 
of ezrin protein level by expression of ezrin siRNA. C, Cell wound-migration assay. LMP1-
enhanced cell migration is reduced by ezrin siRNA. Migration of NP69 cells was measured 
24 h after scratching monolayer cultures at five locations in triplicate after 24 h. Each 
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column represents five independent replicates, and error bars represent ± S.D. Difference 
was tested by paired t test. *indicates statistically significant (p=0.0003) compared with 
control NP69 cells. **indicates significant (p=0.0007) compared with LMP1-expressing 
NP69 +control siRNA cells. Bar=200 μm D, Invasiveness of cells in Matrigel assays. Cells 
on lower surface of filters were fixed and stained. Bar=50 μm. LMP1-enhanced invasiveness 
is suppressed by expression of ezrin siRNA. #, p=0.0011, compared with control NP69 
cells. ##, p=0.0038, compared with LMP1-expressing NP69 +control siRNA cells
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Inhibition of PKC kinase but not ROCK kinase decreases phosphorylation of ezrin. A, 
ROCK inhibitor, Y27632, did not affect LMP1-induced ezrin phosphorylation. B, PKC 
inhibitor, Gö6976, decreases level of LMP1-induced phosphoezrin protein. C, LMP1-
increased cell motility is suppressed by PKC inhibitor. Migration was measured as in the 
legend for Fig. 5. Each column represents five independent replicates, and error bars 
represent ± S.D. Differences were tested by paired t test. *indicates statistically significant 
(p=0.0005) compared with control NP69 cells. **indicates significant (p=0.001) regulation 
after PKC inhibitor treatment. D, LMP1-enhanced invasiveness of NP69 cells is decreased 
by PKC inhibitor. #, p=0.0012, compared with control NP69 cells. ##indicates significant 
effect (p=0.0039) of PKC inhibitor treatment in LMP1-expressing NP69 cells.
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Scheme for proposed mechanism for LMP1-induced phosphorylation of ezrin. LMP1 
enhances phosphorylation of ezrin in its C-terminal region through PKC pathway. 
Phosphorylated ezrin translocates from the cytosol to the plasma membrane and is linked to 
CD44 and actin cytoskeleton. Phosphorylated ezrin contributes to LMP1-induced changes in 
cell phenotype, cell motility and invasiveness in NPC.
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